Autotelic Bio made an agreement with ST Pharm about manufacturing & supplying Trabedersen for the immnuno-oncology treatment drug candidate 'ATB-301(Trabedersen and IL-2 combination therapy)...This is the first step for global expansion of next generation of immuno-oncology new drug candidate "ATB-301"

Autotelic Bio Immuno-oncology new drug candidate ‘ATB-301’ was selected as a designated product for pharmaceutical product commercialization by MFDS Pharm Navi project….

AutotelicBio & Jeil Pharm signed a joint development and technology transfer agreement for ATB-101 (Hypertension/Diabetes Incrementally modified drug)...

Develop immuno-oncology drugs of which side effects are minimized and which are possible for combination therapy with chemical drugs,,,present a new medical approach to patients who are suffering from cancer

“Accelerating the development of immuno-oncology drug”

Autotelic Bio, a bio startup, located in Chungcheongbuk-do has R & D funding of 500 million matching achievements by selecting a TIPS task